[{"arm_notes": "", "treatment_id": null, "treatment_name": "E04.936;Forty patients with COVID-19 will receive an intravenous infusion of one dose of 1.000.000 umbilical cord mesenchymal cells per kilo of the patient. Twenty patients will receive a placebo (saline; albumin and heparin). Conventional treatment will be performed together with the infusion of cells; during the study period. The evaluation times will be at pre-infusion; 6 and 24 hours; days 5 and 28 and 6 months. The patient exams performed: serology; Biochemistry; blood count and blood gas analysis; CT-scan and X-ray; cytokines; viral load; cytometry; and clinical evaluation. The patients will be evaluated all the time; during hospitalization period; to assess adverse events", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1334, "treatment_name": "Umbilical cord mesenchymal stem cells", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]